Additional file 1: Figure S1. of CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer

A. EOC in situ surrounded by ascites. Cells Epcam− (red gate) were cell sorted and cultured. B. Phase contrast pictures of cells sorted in A. Scale bar: 50 μm C. Flow cytometry for every MSC markers on cells sorted in A. D. Cell sorted in fig. 1a were cultured for few days and stained with CD29 (green), CD105 (green), CD90 (red), CD73 (red) antibodies. Scale: 10 μm. Figure S2. OCCs were treated for 48 h with a blocking antibody against IL-6 (20 μg/mL). The percentage of live cells (green gate), apoptotic cells (red gate) and dead cells (black gate) are represented on the plot. Figure S3. A. Paraffin-embedded vimentin immunohistochemistry for the mouse group Control + MSC and Chemo + MSC. B. Confocal images for Epcam on 10μm sections of snap-frozen tumors. Scale: 100 μm. Figure S4. A. Relative quantification of IL-6 gene in RT-PCR on Ovcar3 (orange) and APOCC (purple) treated with SH IL-6 (SH) or scrambled (Scr), and MSC (grey) before (No cocu) or after co-incubation with OCCs scr or SH for 48 h. The histogram represents ratios between the transwell and the control condition of their 2–ΔΔCp real-time PCR values. B. Acquisition of the membrane in chemiluminescence. C. Hierarchical representation of the pixel density of each dot of the cytokine array. Figure S5. Phase contrast of OCCs after treatment with IL-8 (50 ng/ml), Dkk1 (20 ng/ml), IL-6 (50 ng/ml), MCP-1 (10 nM), CCL5 (100 ng/ml), CXCL12 (100 ng/ml), bFGF (10 ng/ml) for 48 h prior treatment with Carboplatin (200 μM) and Taxol (0.1 μM) for 24 h. Figure S6. A. Proteome profiler human phosphokinase array. B. Proteome profiler human phosphokinase array. C. Fold increase of pixel density of each condition compared to APOCC control (blue part) or to APOCC SH-IL6 (purple part). (PDF 1100 kb

Additional file 2: Table S1. of CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer

Primers list. (DOCX 14 kb

Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery

<div><p>Background</p><p>The poor prognosis of patients who experience ipsilateral breast tumor recurrence (IBTR) after breast conserving surgery (BCS) is established. A short time between primary cancer and IBTR is a prognostic factor but no clinically relevant threshold was determined. Classification of IBTR may help tailor treatment strategies.</p><p>Purpose</p><p>We determined a specific time frame, which differentiates IBTR into early and late recurrence, and identified prognostic factors for patients with IBTR at time of the recurrence.</p><p>Methods</p><p>We analyzed 2209 patients with IBTR after BCS. We applied the optimal cut-points method for survival data to determine the cut-off times to IBTR. A subgroup analysis was performed by hormone receptor (HR) status. Survival analyses were performed using a Cox proportional hazard model to determine clinical features associated with distant-disease-free survival (DDFS) after IBTR. We therefor built decision trees.</p><p>Results</p><p>On the 828 metastatic events observed, the majority occurred within the first 3 months after IBTR: 157 in the HR positive group, 98 in the HR negative group. We found different prognostic times to IBTR: 49 months in the HR positive group, 33 in the HR negative group. After multivariate analysis, time to IBTR was the first discriminant prognostic factor in both groups (HR 0.65 CI95% [0.54–0.79] and 0.42 [0.30–0.57] respectively). The other following variables were significantly correlated with the DDFS: the initial number of positive lymph nodes for both groups, the initial tumor size and grade for HR positive tumors.</p><p>Conclusion</p><p>A short interval time to IBTR is the strongest factor of poor prognosis and reflects occult distant disease. It would appear that prognosis after IBTR depends more on clinical and histological parameters than on surgical treatment. A prospective trial in a low-risk group of patients to validate the safety of salvage BCS instead of mastectomy in IBTR is needed.</p></div

Decision tree algorithm HR = hazard ratio for distant disease at 10 years.

<p>(A) Patients with hormone receptor positive tumors. (B) Patients with hormone receptor negative tumors.</p

Distant disease free survival curves according prognostic subgroup.

<p>(A) Patients with hormone receptor positive tumors. (B) Patients with hormone receptor negative tumors.</p

Cutpoint determination.

<p>(larger values indicate cut point more likely here). (A) Patients with hormone receptor positive tumors: 49 months. (B) Patients with hormone receptor negative tumors: 33 months.</p

Distant disease occurrence according to time after IBTR for overall population.

<p>Vertical bars represent the number of events. Width of vertical bars stands for 3 months.</p

Initial characteristics of the population with ipsilateral Breast Cancer Recurrence, at time of primary cancer.

<p>Initial characteristics of the population with ipsilateral Breast Cancer Recurrence, at time of primary cancer.</p

Prognostic factors for post relapse disease free survival–hormone receptor negative tumors.

<p>Prognostic factors for post relapse disease free survival–hormone receptor negative tumors.</p

Prognostic factors for post relapse disease free survival–hormone receptor positive tumors.

<p>Prognostic factors for post relapse disease free survival–hormone receptor positive tumors.</p